Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Diabete Mellitus
- Main trialPhase 4
- “This study is a multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of DA-5218 in patients with type 2 diabetes who have inadequate glycemic control with metformin”In the company’s words, NCT07229534 on ClinicalTrials.gov
Other drugs for Diabete Mellitus
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- QLG1091Qilu Pharmaceutical · Phase 3
- SHR-3167Hengrui · Phase 3
- Maridebart cafraglutideAmgen · Phase 3
- LenbelintideAstraZeneca · Phase 3
Coming up1
- Nov 2027Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Not yet recruiting | Nov 2027 | Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes | |
| Phase 1Unknown | 3 Sep 2022 | Pharmacokinetics and Safety Profiles After Administration of DA-5218 and Co-administration of DA-5218-R1, DA-5218-R2 and DA-5218-R3 in Healthy Adult Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026